Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
"Randomized, Open Label, Non-inferiority Study of Micafungin Versus Standard Care for the Prevention of Invasive Fungal Disease in High Risk Liver Transplant Recipients "	Astellas	Completed	Micafungin	3b	9463EC0001	NGHA-R
"Randomized, Embedded, Multifactorial Adaptive Platform trial for Community- Acquired Pneumonia (REMAP-CAP)"	KAIMRC	Ongoing	Ceftriaxone - Piperacillin Tazobactam - Azithromycin - Interferon β1-a - Hydrocortisone sodium suc... - Hydroxychloroquine - OSELTAMIVIR - Lopinavir-Ritonavir	3	CT20/001/R	NGHA-R
Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Solifenacin succinate film-coated tablets (10 mg solifenacin succinate) versus Vesicare® film-coated tablets (10 mg solifenacin succinate), in healthy subjects under fasting condition.	SPIMACO ADDWAEIH	Ongoing	solifenacin succinate	1, BE	42767	Saudi Ajal
Randomized, two-way, two-period, single injectable dose, open-label, crossover, bioequivalence study to compare Enoxa pre-filled syringes (80 mg enoxaparin sodium) versus Clexane® pre-filled syringes (80 mg enoxaparin sodium), in healthy subjects under fasting condition.	MEDIS Laboratories	Ongoing	Enoxa / Enoxaparin	3, BE	21-2017	Saudi Ajal
Randomized, four-way, four-period, single oral dose, open-label, crossover, bioequivalence study to compare Tacrolimus Immediate-release capsules (5 mg tacrolimus) versus Prograf® Immediate-release capsules (5 mg tacrolimus), in healthy subjects under fasting conditions.	MEDIS Laboratories	Ongoing	Tacrolimus/ Prograf	1, BE	19-2017	Saudi Ajal
Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma	King Faisal Specialist Hospital and Research Centre	Ongoing	Sorafenib (Nexavar)	3	RTOG 1112	KFSH & RC-R
"Randomized clinical trial of neoadjuvant chemotherapy with denosumab compared to chemotherapy alone in hormonal receptor-positive, HER2-negative premenopausal breast cancer patients"	King Abdullah Medical City	Ongoing	DENOSUMAB	3	20-610	King Abdullah Medical City (Makkah)
"randomised, multicentre, double-blind, placebo-controlled study of ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH)"	GSK	Completed	Ambrisentan 5 mg	3	AMB115811	KFMC
RAINBOW study: a randomized, controlled study evaluating the efficacy and safety of Ranibizumab compared with laser therapy for the treatment of Infants BOrn prematurely With retinopathy of prematurity	Novartis	Ongoing	Ranibizumab	3	CRFB002H2301 V 01	KFSH & RC-R
"PROSPECTIVE, RANDOMIZED, OPEN LABEL CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF DEXMEDETOMIDINE USE BEYOND 24 HOURS COMPARED WITH MIDAZOLAM IN CHILDREN ADMITTED TO PEDIATRIC INTENSIVE CARE UNIT (PICU) AT KASCH-MNGHA. (PROMISE)"	KAIMRC	Rejected	Dexmedetomidine (Hospira)	3	RC20/160/R	King Abdulaziz Medical City NG (Riyadh)